{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:39:35Z","timestamp":1761007175743,"version":"build-2065373602"},"reference-count":83,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.soc.2008.04.011","type":"journal-article","created":{"date-parts":[[2008,8,23]],"date-time":"2008-08-23T09:04:42Z","timestamp":1219482282000},"page":"857-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Development of Isolated Hepatic Perfusion for Patients Who Have Unresectable Hepatic Malignancies"],"prefix":"10.1016","volume":"17","author":[{"given":"Adriana","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"H. Richard","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.soc.2008.04.011_bib1","first-page":"106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.soc.2008.04.011_bib2","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.00.349","article-title":"Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2008.04.011_bib3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(196901)23:1<198::AID-CNCR2820230126>3.0.CO;2-J","article-title":"The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy","volume":"23","author":"Bengmark","year":"1969","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2008.04.011_bib4","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.soc.2008.04.011_bib5","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1200\/JCO.2005.00.232","article-title":"Combined analysis of efficacy: the addition of bevacizumab to fluorouracil\/leucovorin improves survival for patients with metastatic colorectal cancer","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.soc.2008.04.011_bib6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/01.sla.0000128305.90650.71","article-title":"Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection\/ablation for colorectal liver metastases","volume":"239","author":"Abdalla","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.soc.2008.04.011_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-642-82025-0_18","article-title":"First experimental and clinical results of isolated liver perfusion with cytotoxics in metastases from colorectal primary","volume":"86","author":"Aigner","year":"1983","journal-title":"Recent Results Cancer Res"},{"issue":"3","key":"10.1016\/j.soc.2008.04.011_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.soc.2008.04.011_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1245\/ASO.2004.07.004","article-title":"Regional treatment options for patients with ocular melanoma metastatic to the liver","volume":"11","author":"Feldman","year":"2004","journal-title":"Ann Surg Oncol"},{"issue":"31","key":"10.1016\/j.soc.2008.04.011_bib10","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.1200\/JCO.2005.02.6534","article-title":"Variates of survival in metastatic uveal melanoma","volume":"23","author":"Rietschel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2008.04.011_bib11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/1097-0142(19830715)52:2<334::AID-CNCR2820520225>3.0.CO;2-E","article-title":"Survival in metastatic ocular melanoma","volume":"52","author":"Rajpal","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2008.04.011_bib12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0161-6420(91)32285-1","article-title":"Survival of patients with metastases from uveal melanoma","volume":"98","author":"Gragoudas","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.soc.2008.04.011_bib13","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/1097-0142(19931001)72:7<2219::AID-CNCR2820720725>3.0.CO;2-J","article-title":"Prognosis and treatment of disseminated uveal melanoma","volume":"72","author":"Kath","year":"1993","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.soc.2008.04.011_bib14","first-page":"187","article-title":"Gastrointestinal neuroendocrine tumors","volume":"178","author":"Delcore","year":"1994","journal-title":"J Am Coll Surg"},{"issue":"4","key":"10.1016\/j.soc.2008.04.011_bib15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2","article-title":"An analysis of 8305 cases of carcinoid tumors","volume":"79","author":"Modlin","year":"1997","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.soc.2008.04.011_bib16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1072-7515(00)00222-2","article-title":"Hepatic neuroendocrine metastases: does intervention alter outcomes?","volume":"190","author":"Chamberlain","year":"2000","journal-title":"J Am Coll Surg"},{"issue":"4","key":"10.1016\/j.soc.2008.04.011_bib17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bpg.2005.04.003","article-title":"Endocrine tumours of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases","volume":"19","author":"Norton","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.soc.2008.04.011_bib18","first-page":"S169","article-title":"Treatment of patients with hepatic metastases","volume":"6","author":"Bartlett","year":"2000","journal-title":"Cancer J"},{"issue":"2","key":"10.1016\/j.soc.2008.04.011_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00130404-200203000-00012","article-title":"Isolation perfusion of the liver","volume":"8","author":"Carroll","year":"2002","journal-title":"Cancer J"},{"issue":"16","key":"10.1016\/j.soc.2008.04.011_bib20","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"issue":"9079","key":"10.1016\/j.soc.2008.04.011_bib21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(97)03358-8","article-title":"Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy","volume":"350","author":"Levi","year":"1997","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.soc.2008.04.011_bib22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.soc.2008.04.011_bib23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1634\/theoncologist.9-6-653","article-title":"The past decade of experience with isolated hepatic perfusion","volume":"9","author":"Grover","year":"2004","journal-title":"Oncologist"},{"issue":"23","key":"10.1016\/j.soc.2008.04.011_bib24","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.soc.2008.04.011_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.soc.2008.04.011_bib26","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","article-title":"Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2008.04.011_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1245\/ASO.2006.03.094","article-title":"Treatment with 5-fluorouracil\/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer","volume":"13","author":"Masi","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2008.04.011_bib28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1023\/A:1008347829017","article-title":"Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery","volume":"10","author":"Giacchetti","year":"1999","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.soc.2008.04.011_bib29","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","article-title":"Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial","volume":"21","author":"Rothenberg","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2008.04.011_bib30","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1200\/JCO.1997.15.7.2589","article-title":"Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy","volume":"15","author":"Leyvraz","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2008.04.011_bib31","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.1988.03410070102037","article-title":"Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge","volume":"260","author":"Mavligit","year":"1988","journal-title":"JAMA"},{"issue":"1-2","key":"10.1016\/j.soc.2008.04.011_bib32","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0041-1345(00)02586-0","article-title":"Resection versus transplantation for liver metastases from neuroendocrine tumors","volume":"33","author":"Coppa","year":"2001","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1016\/j.soc.2008.04.011_bib33","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdf064","article-title":"Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours","volume":"13","author":"Bajetta","year":"2002","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.soc.2008.04.011_bib34","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s10620-006-8001-3","article-title":"A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors","volume":"51","author":"Kulke","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.soc.2008.04.011_bib35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00130404-200307000-00008","article-title":"Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience","volume":"9","author":"Gupta","year":"2003","journal-title":"Cancer J"},{"issue":"6","key":"10.1016\/j.soc.2008.04.011_bib36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/01.cad.0000210335.95828.ed","article-title":"Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors","volume":"17","author":"Kvols","year":"2006","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.soc.2008.04.011_bib37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/107327480601300107","article-title":"Radiofrequency ablation of liver metastases from colorectal carcinoma","volume":"13","author":"Feliberti","year":"2006","journal-title":"Cancer Control"},{"issue":"9","key":"10.1016\/j.soc.2008.04.011_bib38","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2005.03.8166","article-title":"Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)","volume":"24","author":"Kemeny","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2008.04.011_bib39","first-page":"969","article-title":"Blood supply of neoplasms of the liver","volume":"30","author":"Breedis","year":"1954","journal-title":"Am J Pathol"},{"key":"10.1016\/j.soc.2008.04.011_bib40","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1200\/JCO.1987.5.11.1836","article-title":"Tumor and liver drug uptake following hepatic artery and portal vein infusion in man","volume":"5","author":"Sigurdson","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2008.04.011_bib41","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/(SICI)1098-2388(199611\/12)12:6<416::AID-SSU7>3.0.CO;2-D","article-title":"Isolated limb perfusion for malignant melanoma","volume":"12","author":"Alexander","year":"1996","journal-title":"Semin Surg Oncol"},{"key":"10.1016\/j.soc.2008.04.011_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1992.10.1.52","article-title":"High dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma","volume":"10","author":"Lienard","year":"1992","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.soc.2008.04.011_bib43","first-page":"2357","article-title":"Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor independent mechanisms","volume":"4","author":"Alexander","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.soc.2008.04.011_bib44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<215::AID-SSU5>3.0.CO;2-B","article-title":"The application of hyperthermia in regional chemotherapy","volume":"14","author":"di Filippo","year":"1998","journal-title":"Semin Surg Oncol"},{"key":"10.1016\/j.soc.2008.04.011_bib45","first-page":"3393","article-title":"Development of a technic for isolated perfusion of the liver","volume":"61","author":"Ausman","year":"1961","journal-title":"N Y State J Med"},{"key":"10.1016\/j.soc.2008.04.011_bib46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000415979","article-title":"Isolated liver perfusion with MMC\/5-FU\u2014surgical technique, pharmacokinetics, clinical results","volume":"29","author":"Aigner","year":"1988","journal-title":"Contributions in Oncology"},{"key":"10.1016\/j.soc.2008.04.011_bib47","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archsurg.1986.01400110056009","article-title":"Tumoricidal effects and patient survival after hyperthermic liver perfusion","volume":"121","author":"Skibba","year":"1986","journal-title":"Arch Surg"},{"issue":"9","key":"10.1016\/j.soc.2008.04.011_bib48","first-page":"1539","article-title":"Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver","volume":"82","author":"Vahrmeijer","year":"2000","journal-title":"Br J\u00a0Cancer"},{"key":"10.1016\/j.soc.2008.04.011_bib49","article-title":"Treatment of unresectable cancers confined to liver using vascular isolation and perfusion","volume":"vol. 15","author":"Alexander","year":"2001"},{"issue":"6","key":"10.1016\/j.soc.2008.04.011_bib50","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.surg.2004.06.044","article-title":"Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms","volume":"136","author":"Grover","year":"2004","journal-title":"Surgery"},{"issue":"17","key":"10.1016\/j.soc.2008.04.011_bib51","first-page":"6343","article-title":"Hyperthermic isolated hepatic perfusion (IHP) using melphalan for patients with ocular melanoma metastatic to liver","volume":"9","author":"Alexander","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.soc.2008.04.011_bib52","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1245\/ASO.2005.05.003","article-title":"Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy","volume":"12","author":"Alexander","year":"2005","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2008.04.011_bib53","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1072-7515(00)00733-X","article-title":"Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies","volume":"191","author":"Libutti","year":"2000","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.soc.2008.04.011_bib54","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0039-6060(98)70200-4","article-title":"First experience and technical aspects of isolated liver perfusion for extensive liver metastasis","volume":"123","author":"Oldhafer","year":"1998","journal-title":"Surgery"},{"key":"10.1016\/j.soc.2008.04.011_bib55","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1634\/theoncologist.5-5-416","article-title":"Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver","volume":"5","author":"Alexander","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.soc.2008.04.011_bib56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/jso.2930270303","article-title":"A technique for isolated hyperthermic liver perfusion","volume":"27","author":"Quebbeman","year":"1984","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.soc.2008.04.011_bib57","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/BF00299083","article-title":"Simple method of hyperthermo-chemo-hypoxic isolated liver perfusion for hepatic metastases","volume":"18","author":"Horikawa","year":"1994","journal-title":"World J Surg"},{"key":"10.1016\/j.soc.2008.04.011_bib58","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/BF01655820","article-title":"Rationale and indications for perfusion in liver tumors: current data","volume":"11","author":"Schwemmle","year":"1987","journal-title":"World J Surg"},{"key":"10.1016\/j.soc.2008.04.011_bib59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0960-7404(94)90005-1","article-title":"Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy","volume":"3","author":"Hafstr\u00f6m","year":"1994","journal-title":"Surg Oncol"},{"key":"10.1016\/j.soc.2008.04.011_bib60","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/BF00299787","article-title":"Leukocyte activation by isolated hyperthermic liver and limb perfusion due to malignancy","volume":"19","author":"Arnestad","year":"1995","journal-title":"World J Surg"},{"key":"10.1016\/j.soc.2008.04.011_bib61","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/bjs.1800790932","article-title":"Isolated hyperthermic liver perfusion with cytostatic-containing perfusate activates the complement cascade","volume":"79","author":"Arnestad","year":"1992","journal-title":"Br J Surg"},{"key":"10.1016\/j.soc.2008.04.011_bib62","first-page":"254","article-title":"Pharmacokinetics of cisplatin in an isolated liver perfusion system in humans","volume":"4","author":"Naredi","year":"1992","journal-title":"Reg Cancer Treat"},{"key":"10.1016\/j.soc.2008.04.011_bib63","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/978-3-642-80460-1_12","article-title":"Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia TNF\u03b1 and melphalan: Swedish experience","volume":"147","author":"Hafstr\u00f6m","year":"1998","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.soc.2008.04.011_bib64","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.jjco.a023243","article-title":"Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver","volume":"26","author":"Marinelli","year":"1996","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.soc.2008.04.011_bib65","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-642-80460-1_9","article-title":"Phase I\/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases","volume":"147","author":"Marinelli","year":"1998","journal-title":"Recent Results Cancer Res"},{"issue":"4","key":"10.1016\/j.soc.2008.04.011_bib66","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.1998.16.4.1479","article-title":"Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver","volume":"16","author":"Alexander","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2008.04.011_bib67","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-642-80460-1_11","article-title":"Isolated hepatic perfusion with tumor necrosis factor \u03b1 and melphalan: experimental studies in pigs and phase I data from humans","volume":"147","author":"de Vries","year":"1998","journal-title":"Recent Results Cancer Res"},{"issue":"6","key":"10.1016\/j.soc.2008.04.011_bib68","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1365-2362.1999.00480.x","article-title":"Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases","volume":"29","author":"De Vries","year":"1999","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"10.1016\/j.soc.2008.04.011_bib69","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/bjc.1997.255","article-title":"Liver and tumour tissue concentrations of TNF-\u03b1 in cancer patients treated with TNF-\u03b1 and melphalan by isolated liver perfusion","volume":"75","author":"Kuppen","year":"1997","journal-title":"Br J\u00a0Cancer"},{"issue":"11","key":"10.1016\/j.soc.2008.04.011_bib70","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/bjs.4308","article-title":"Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver","volume":"90","author":"Rothbarth","year":"2003","journal-title":"Br J Surg"},{"key":"10.1016\/j.soc.2008.04.011_bib71","series-title":"Current clinical oncology: regional chemotherapy: clinical research and practice","first-page":"127","article-title":"National Cancer Institute experience with regional therapy for unresectable primary and metastatic cancer of the liver or peritoneal cavity","author":"Alexander","year":"2000"},{"issue":"2","key":"10.1016\/j.soc.2008.04.011_bib72","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/00130404-200403000-00008","article-title":"Current role of hepatic artery infusion and isolated liver perfusion for the treatment of colorectal cancer liver metastases","volume":"10","author":"Elaraj","year":"2004","journal-title":"Cancer J"},{"key":"10.1016\/j.soc.2008.04.011_bib73","first-page":"2","article-title":"Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancers confined to the liver","volume":"4","author":"Alexander","year":"1998","journal-title":"Cancer J\u00a0Sci Am"},{"issue":"2","key":"10.1016\/j.soc.2008.04.011_bib74","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1067\/msy.2001.110365","article-title":"Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer","volume":"129","author":"Bartlett","year":"2001","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.soc.2008.04.011_bib75","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cncr.10686","article-title":"Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy","volume":"95","author":"Alexander","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.soc.2008.04.011_bib76","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1245\/ASO.2005.05.003","article-title":"Isolated hepatic perfusion for the treatment of patients with colorectal cancer (CRC) liver metastases after irinotecan-based therapy","volume":"12","author":"Alexander","year":"2005","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2008.04.011_bib77","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.soc.2008.04.011_bib78","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.ejca.2004.04.009","article-title":"Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives","volume":"40","author":"Rothbarth","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.soc.2008.04.011_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/0-387-29512-7_1","article-title":"Isolated hepatic perfusion: treating unresectable liver metastases","volume":"574","author":"Farma","year":"2006","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.soc.2008.04.011_bib80","first-page":"S18","article-title":"A phase I feasibility study of hepatic arterial melphalan infusion with hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies","volume":"10","author":"Pingpank","year":"2003","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2008.04.011_bib81","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archsurg.138.3.325","article-title":"Percutaneous isolated hepatic perfusion for chemotherapy: a phase 1 study","volume":"138","author":"Savier","year":"2003","journal-title":"Arch Surg"},{"key":"10.1016\/j.soc.2008.04.011_bib82","first-page":"3062","article-title":"A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver","volume":"6","author":"Alexander","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.soc.2008.04.011_bib83","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00008390-200402000-00011","article-title":"Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver","volume":"14","author":"Noter","year":"2004","journal-title":"Melanoma Res"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320708000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320708000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:54:47Z","timestamp":1760961287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320708000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S1055320708000355"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2008.04.011","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Isolated Hepatic Perfusion for Patients Who Have Unresectable Hepatic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2008.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}